(RDNT) RadNet - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7504911022

RDNT: Medical Imaging, Artificial Intelligence, Diagnostic Services

RADNET (NASDAQ:RDNT) operates as a leading provider of outpatient diagnostic imaging services across the United States. With a strong market position in high-demand regions like California and the Northeast, the company has built a scalable platform that combines traditional imaging services with cutting-edge AI-driven diagnostic tools. Founded in 1981, RadNet has established itself as a key player in the diagnostics space, with a market capitalization of over $4.6 billion, reflecting its scale and growth prospects.

The company’s core business revolves around its Imaging Centers segment, which offers a wide range of diagnostic services, including MRI, CT scans, PET scans, mammography, ultrasound, and fluoroscopy. This diversified service offering allows RadNet to cater to a broad patient base, making it a one-stop solution for outpatient imaging needs. The company’s extensive network of imaging centers ensures high accessibility and convenience for both patients and healthcare providers.

What sets RadNet apart is its growing focus on Artificial Intelligence. The company has made significant strides in developing AI-powered solutions designed to enhance radiologist workflows and improve diagnostic accuracy. For instance, its AI suites are specifically tailored to improve the interpretation of breast, lung, and prostate images, addressing some of the most critical areas in cancer screening. This integration of AI not only enhances patient outcomes but also positions RadNet as a forward-thinking leader in the diagnostics industry.

From a financial perspective, RadNet’s valuation metrics highlight its growth trajectory. With a price-to-sales ratio of 2.62 and a price-to-book ratio of 5.19, the company is trading at a premium, reflecting investor confidence in its ability to scale and innovate. While the current P/E ratio is not meaningful due to earnings volatility, the forward P/E suggests expectations of improving profitability as the company continues to consolidate its market position and expand its AI offerings.

For investors and fund managers, RadNet represents a compelling opportunity to invest in the intersection of healthcare and technology. The company’s strong market position, recurring revenue model, and strategic focus on AI-driven innovation make it a standout player in the diagnostics space. As the healthcare industry continues to shift toward value-based care and precision medicine, RadNet is well-positioned to benefit from these trends, making it a strategic addition to portfolios with a long-term horizon.

Additional Sources for RDNT Stock

RDNT Stock Overview

Market Cap in USD 3,819m
Sector Healthcare
Industry Diagnostics & Research
GiC Sub-Industry Health Care Services
IPO / Inception 1986-07-01

RDNT Stock Ratings

Growth 5y 78.7%
Fundamental 23.2%
Dividend 0.0%
Rel. Strength Industry 5.16
Analysts 4.5/5
Fair Price Momentum 46.94 USD
Fair Price DCF 9.06 USD

RDNT Dividends

No Dividends Paid

RDNT Growth Ratios

Growth Correlation 3m -91.8%
Growth Correlation 12m 58.9%
Growth Correlation 5y 81%
CAGR 5y 34.55%
CAGR/Max DD 5y 0.57
Sharpe Ratio 12m -0.17
Alpha -6.82
Beta 1.34
Volatility 61.44%
Current Volume 1140.3k
Average Volume 20d 914k
What is the price of RDNT stocks?
As of March 15, 2025, the stock is trading at USD 46.54 with a total of 1,140,338 shares traded.
Over the past week, the price has changed by -7.49%, over one month by -24.12%, over three months by -40.32% and over the past year by +6.09%.
Is RadNet a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, RadNet is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 23.22 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RDNT as of March 2025 is 46.94. This means that RDNT is currently overvalued and has a potential downside of 0.86%.
Is RDNT a buy, sell or hold?
RadNet has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy RDNT.
  • Strong Buy: 3
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for RDNT stock price target?
According to ValueRays Forecast Model, RDNT RadNet will be worth about 52 in March 2026. The stock is currently trading at 46.54. This means that the stock has a potential upside of +11.82%.
Issuer Forecast Upside
Wallstreet Target Price 77.7 66.9%
Analysts Target Price 90.2 93.7%
ValueRay Target Price 52 11.8%